Thalidomide in multiple myeloma: current status and future prospects
- 20 December 2002
- journal article
- guideline
- Published by Wiley in British Journal of Haematology
- Vol. 120 (1), 18-26
- https://doi.org/10.1046/j.1365-2141.2003.03902.x
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Thalidomide in the management of multiple myelomaSeminars in Hematology, 2001
- Deep Venous Thrombosis and Thalidomide Therapy for Multiple MyelomaNew England Journal of Medicine, 2001
- Life-Threatening Toxic Epidermal Necrolysis with Thalidomide Therapy for MyelomaNew England Journal of Medicine, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascadeImmunopharmacology, 1996
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Guideline for the clinical use and dispensing of thalidomidePublished by Oxford University Press (OUP) ,1994
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993